<DOC>
	<DOCNO>NCT02883803</DOCNO>
	<brief_summary>The purpose determine effect mesenchymal stem cell administer early phase septic shock evolution organ failure assess SOFA score ( Sepsis Organ Failure Assessment score ) day 7 ( death day day recovery unit exit day 7 ) compare observed group control patient . The secondary purpose assess role heterologous mesenchymal stem cell occurrence duration failure organ mortality day 28 day 90 . The safety administration also assess .</brief_summary>
	<brief_title>Effects Administration Mesenchymal Stem Cells Organ Failure During Septic Shock</brief_title>
	<detailed_description>Patients hospitalized recovery unit severe septic shock community origin ( ≥ 2 organ failure hemodynamic ) since less 12 hour , receive 10^6/kg heterologous mesenchymal stem cell 250 ml albumin 4 % , infuse 30 minute central venous line 250 ml albumin 4 % alone .</detailed_description>
	<mesh_term>Shock</mesh_term>
	<mesh_term>Shock , Septic</mesh_term>
	<criteria>Septic shock community origin since less 12 hour . The onset time septic shock time catecholamine introduction ( adrenaline , noradrenaline , dopamine &gt; 8μg/kg/min ) At least 2 organ failure hemodynamic Occurrence Monday 8am Friday 8am ( availability reason staff ) Signature inform consent ( patient/close relative reliable person ) Affiliation social security plan Nonseptic shock Nosocomial septic shock PaO2/FiO2 &lt; 100 Pregnant breastfeed woman Brain death Dying person Therapeutic limitation Participation another current interventional clinical trial since less 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>